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Abstract
Duchenne muscular dystrophy is a progressive and incurable neuromuscular disease caused by 
genetic and biochemical defects of the dystrophin-glycoprotein complex. Here we show the 
regenerative potential of myogenic progenitors derived from corrected dystrophic induced 
pluripotent stem (iPS) cells generated from fibroblasts of mice lacking both dystrophin and 
utrophin. We correct the phenotype of dystrophic iPS cells using a Sleeping Beauty transposon 
carrying the micro-utrophin (μUTRN) gene, differentiate these cells into skeletal muscle 
progenitors, and transplant them back into dystrophic mice. Engrafted muscles displayed large 
numbers of micro-utrophin-positive myofibers, with biochemically restored dystrophin-
glycoprotein complex and improved contractile strength. The transplanted cells seed the satellite 
cell compartment, responded properly to injury and exhibit neuromuscular synapses. We also 
detect muscle engraftment after systemic delivery of these corrected progenitors. These results 
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represent an important advance toward the future treatment of muscular dystrophies using 
genetically corrected autologous iPS cells.
INTRODUCTION
Pluripotent stem cells are particularly attractive for therapeutic application as these cells are 
endowed with robust expansion potential, enabling the generation of large quantities of 
tissue-specific stem/progenitor cell preparations. This is extremely beneficial as cell number 
has been one of the main barriers to implementing cell-based therapies. iPS technology 1–4 
further allows for the derivation of patient-specific pluripotent stem cell preparations 
without the ethical and immunological concerns associated with human embryonic stem 
(ES) cells. In the case of muscular dystrophies, either allogeneic or autologous cell 
transplantations have the potential to lead to an effective treatment. For allogeneic 
transplantation, one would utilize iPS-derived myogenic progenitors obtained from a healthy 
HLA-matched donor, which following transplantation would give rise to new healthy 
myofibers as well as fuse to the recipient’s myofibers, to generate hybrid myofibers that 
express dystrophin. The autologous approach would require ex vivo genetic correction of 
dystrophic iPS cells prior to transplantation. Despite extensive research in iPS technology, to 
date there are only two reports on the therapeutic potential of disease-specific iPS cells that 
have been genetically corrected, transplanted back into an appropriate mouse model and 
shown to provide therapeutic benefit: for sickle cell anemia 5 and β-thalassemia 6. Genetic 
correction for muscular dystrophies has been tested with some success in 
mesoangioblasts 7–9 however these somatic cells have reported limited expansion 
potential 10. The deficit in translational studies involving genetically-corrected iPS cells is 
most likely due to the difficulty in coaxing pluripotent stem cells to become lineage-specific 
stem cells that are able to produce functional tissue in vivo.
We developed and continued to improve a method to efficiently generate skeletal muscle 
stem/progenitor cells endowed with significant regeneration potential through Pax3 or Pax7 
induction in control ES and iPS cells 11–14. In the present study we show proof-of-principle 
for the ex vivo gene correction of mouse dystrophic iPS cells. We inserted the micro-
utrophin (μUTRN) gene into iPS cells obtained from dystrophin/utrophin double knockout 
mice (dKO) using the Sleeping Beauty transposon system, and demonstrated that skeletal 
myogenic progenitors derived from gene corrected iPS cells have the capacity to promote 
substantial muscle regeneration in vivo when transplanted back in dKO mice, and that 
engraftment is accompanied by functional improvement.
RESULTS
Characterization and correction of dystrophic iPS cells
To address the feasibility of using disease-specific iPS cells and genetic correction in the 
context of DMD, we utilized the dystrophin/utrophin double knockout mouse model (dKO) 
as the source of tail tip fibroblasts (TTF) as well as recipients of iPS-derived therapeutic 
myogenic cell preparations (Fig. 1a). This choice was based on the fact that mdx mice, 
although a favorite model for DMD 15, present a mild phenotype, attributed to compensatory 
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overexpression of the dystrophin-related protein, utrophin 16. The dKO mice, which lack 
both dystrophin and utrophin, present a severe phenotype characterized by progressive 
muscle wasting, impaired mobility, abnormal breathing pattern, cardiomyopathy, and 
premature death 17,18, which more closely resembles DMD in human patients. To restore the 
DGC, we chose to re-express a micro-utrophin transgene, which has been shown to 
ameliorate the dystrophic phenotype 19–22. This approach tests a vector that would 
potentially be preferred in human patients since it would avoid the immune response that is 
elicited by the dystrophin-naive immune system (the mouse model tests function of μUTRN 
in this context but not immune aspects). As summarized in Figure 1a, the therapeutic 
strategy applied in the present study involved (1) reprogramming of dystrophic donor 
fibroblasts into iPS clones, (2) genetic repair of selected iPS clones with μUTRN using the 
non-viral Sleeping Beauty System, (3) in vitro differentiation of corrected iPS cell clones 
into myogenic progenitors, and (4) transplantation of corrected myogenic precursors into 
dystrophic dKO mice (mdx;utrn−/−).
Dystrophic iPS cells were generated by retroviral transduction of tail tip fibroblast (TTF) 
cells using Oct4, Klf4, and Sox2 23. iPS clones were initially screened by morphology, 
SSEA-1 expression, and alkaline phosphatase activity (Supplementary Fig. S1a–b). Based 
on these markers, a subset of clones was selected for additional analysis, which included 
immunofluorescence staining to pluripotency markers (Supplementary Fig. S1c), as well as 
assessment of their ability to form embryonic mesoderm following in vitro differentiation 
into embryoid bodies (EBs), as evidenced by Flk-1 and PDGFαR expression 
(Supplementary Fig. S1d–e). After this analysis, one iPS clone (C3) was chosen for the 
studies presented here. These cells displayed normal karyotype and exhibited the ability to 
develop typical teratomas (Supplementary Fig. S1f–g). Importantly, following EB 
differentiation, iPS cells showed down-regulation of pluripotency markers and normal 
expression of imprinted genes (Supplementary Fig. S1h–i, respectively), which has been 
previously shown to distinguish fully-reprogrammed iPS cells 24.
Dystrophic iPS cells were then corrected with the μUTRN transgene (ΔR4-R21). This gene 
is a contracted version of UTRN lacking sequences encoding spectrin-like repeats 4 through 
21, but containing the N-terminal (N) domain that binds to F-actin, and the C-terminal 
domain (C/C cysteine-rich domain) that interacts with the dystrophin-glycoprotein complex. 
This gene complements both the loss of dystrophin and utrophin 20. The Sleeping Beauty 
transposon (Tn) system has several advantages including efficient gene transfer and stable 
gene expression in mouse and human ES cells 25,26, and reduced likelihood of insertional 
mutagenesis 27. We developed a T2 inverted terminal repeat transposon vector (pKt2/μUtrn) 
carrying a 7.3kb engineered transgene containing μUtrophin and an iresGFP reporter (Fig. 
1b), which allows for FACS selection of μUTRN-corrected iPS cells. SB100X (Fig. 1b) is a 
recently engineered hyperactive variant that yields high levels of transposon integration, 
leading to efficient and stable gene transfer 28. We observed a stable gene transfer frequency 
of 0.3% one week after nucleofection with transposon and transposase vectors (Fig 1c). 
GFP+ cells were sorted, expanded, and re-sorted, giving rise to a homogeneous and stable 
population of μUTRN-corrected iPS cells (>90% GFP+) (Fig. 1c and Fig. 1d, right panel). 
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The expression of μUTRN was confirmed by qPCR (Supplementary Fig. S2a). Corrected 
iPS cells maintained a normal karyotype (Supplementary Fig. S2b).
Skeletal myogenic progenitors from gene corrected iPS cells
To enable the efficient generation of skeletal myogenic progenitors, both μUTRN-corrected 
and control (uncorrected) iPS cells (Fig. 1d) were modified to allow doxycycline-regulated 
conditional Pax3 expression, which we have previously shown allows the derivation of 
repopulating myogenic progenitors from ES cells 12 (Supplementary Fig. S3a). Pax3+ cells 
(mCherry+) were detected only when dox was added to the culture medium (Supplementary 
Fig. S3b). This has been confirmed by western blot analysis (Supplementary Fig. S3c). To 
isolate skeletal myogenic precursors, Pax3 was induced from day 3 to day 5 of EB 
differentiation, at which point paraxial mesoderm progenitors were isolated based on the 
expression of PDGFαR and lack of Flk1 (Fig. 1e, left panels) 12. In the case of corrected 
iPS-derived EBs, cells were further purified based on positivity for GFP, which is co-
expressed with μUTRN (Fig. 1e, lower middle panel). Since Pax3 is co-expressed with 
mCherry, both control and corrected dox-induced EBs were mCherry+ (Fig. 1e, right 
panels), while non-induced control counterparts were mCherry− (Supplementary Fig. S3d).
PDGFαR+Flk1−GFP+ sorted cell preparations from corrected iPS-derived EBs (Fig. 1e) 
were expanded in the presence of bFGF and doxycycline. Proliferating myogenic precursors 
emerged from these cultures (Fig. 1f, left panels). When differentiation was induced in vitro, 
these had the ability to undergo final maturation, giving rise to multinucleated myotubes 
(Fig. 1f, right panels) that exhibited elevated fusion index (82% ±8%; Supplementary Fig. 
S3e) (details in methods). Importantly, abundant and stable expression of μUTRN was 
observed in corrected myogenic progenitors and their derivative myotubes, as shown by 
immunofluorescence staining (Fig. 1g), qPCR (Fig. 1h), and western blot analysis (Fig. 1i). 
No utrophin was detected in control uncorrected myogenic preparations (Fig. 1i).
As anticipated, proliferating myogenic progenitors were characterized by abundant 
expression of Pax3 as well as Myf5 (Supplementary Fig. S4a). Under these conditions, 
MyoD was observed in fewer nuclei, while terminal differentiation markers, such as MyHC 
were barely detected (Supplementary Fig. S4a). This profile changed upon induction of 
myogenic differentiation, as multinucleated myotubes expressed high levels of MyHC and 
MyoD, and displayed significant down-regulation of Pax3 and Myf5 (Supplementary Fig. 
S4b). These results were further confirmed by real time RT-PCR (Supplementary Fig. S5). 
Flow cytometric analysis of μUTRN-corrected myogenic progenitors showed homogeneous 
expression of M-cadherin (M-CAD; 99%), CD56 (82%), VCAM1 (85%), SYND-4 (98%), 
and CXCR4 (98%) (Supplementary Fig. S4c), surface markers characteristic of satellite and 
myogenic progenitor cells 29.
Regenerative potential of gene corrected myogenic cells
To assess whether these corrected autologous cells would engraft and differentiate into 
muscle in vivo, μUTRN-corrected iPS-derived myogenic precursors were transplanted into 
the left tibialis anterior (TA) muscles of 3-week old dKO mice, whereas the contra-lateral 
TA (right) was injected with PBS. Because the dKO strain presents a much more severe 
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phenotype, we did not pre-injure with cardiotoxin to enhance engraftment, as previously 
described for transplantations in mdx mice 12. Mice received immunosuppression daily 
(Tacrolimus) as both dystrophin and utrophin are foreign proteins to these mice, in addition 
to GFP. Three weeks following transplantation, cryosections of TA muscles were evaluated 
for engraftment by immunofluorescence staining for utrophin using a polyclonal antibody 
that specifically recognizes the amino-terminal epitope preserved in the μUTRN transgene. 
As expected 17,18, no expression of utrophin was detected in PBS-injected control muscles 
of the contra-lateral leg (Fig. 2a). On the contrary, TA muscles that had been transplanted 
with μUTRN-corrected iPS-derived myogenic precursors demonstrated substantial 
engraftment, as showed by the clear expression of utrophin in recipient muscles (Fig. 2b). 
Quantification of μUtrophin+ myofibers showed engraftment average levels of 19 ± 7.6% in 
transplanted mice (Fig. 2c). Analyses for β-dystroglycan (β-DG), α1-syntrophin (α1-SYN), 
and neuronal nitric oxide synthase (nNOS) in consecutive sections revealed contiguous 
expression of these proteins across long sections of engrafted μUTRN+ myofibers (Fig. 2b). 
These data show that μUTRN-corrected iPS-derived myogenic precursors are able to engraft 
in vivo, and more importantly μUTRN expression was able to restore other components of 
the DGC, which are missing in the absence of dystrophin (Fig. 2a) 17,18,30,31. Another 
critical aspect is that no tumors were detected in any of the transplanted mice (total of 20 
dKO mice) or in NOD/SCID mice injected with these cell preparations up to 3 months post-
transplantation. We have previously shown that by incorporating positive selection for 
paraxial mesoderm markers, teratoma-forming cells can be eliminated from mouse ES-
derived cell preparations 12.
Engrafted corrected cells reestablish functional properties
To investigate whether engraftment was accompanied by improvement in muscle function, 
we evaluated in a blinded manner the contractile properties of transplanted muscles 
compared to their contralateral leg controls. Engrafted muscles showed markedly superior 
isometric tetanic force (Fig. 3a), increased absolute and specific force (Fig. 3b–c, 
respectively) when compared to their respective contralateral PBS-injected TA muscles. No 
changes were observed in CSA (Supplementary Fig. S6c) or weight (Supplementary Fig. 
S6d), as previously observed for ES-derived myogenic progenitors using this delivery 
route 12. Data from the fatigue test showed no differences between transplanted and control 
groups (Fig. 3d), suggesting that levels of engraftment were not sufficient to restore this 
parameter.
Transplanted cells seed the satellite cell compartment
Next we examined whether μUTRN-corrected myogenic precursors have the ability to seed 
the satellite cell compartment and therefore to respond to injury (Supplementary Fig. S6d). 
To facilitate the detection of donor-derived satellite cells, corrected myogenic precursors 
were labeled with a lentiviral vector encoding GFP (Supplementary Fig. S6d). Three weeks 
following transplantation, we could clearly identify the presence of Pax7+GFP+ cells 
beneath the basal lamina (Fig. 3e), indicative of donor-derived satellite cells. This was 
confirmed by another experimental cohort, in which we promoted cardiotoxin (CTX) injury 
in dKO mice that had been transplanted 3 weeks prior with μUTRN-corrected myogenic 
precursors (not labeled with GFP) (Supplementary Fig. S6d). One week after injury we 
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detected the presence of donor-derived newly formed corrected myofibers, as shown by the 
presence of μUTRN+/embryonic MHC+ myofibers (Fig. 3f). Recipient-derived newly 
formed myofibers (μUTRNneg/embryonic MHC+) were found in transplanted mice (Fig. 3f) 
as well as in PBS-injected controls (contra-lateral leg; Supplementary Fig. S6e), as expected. 
The donor-derived newly formed myotubes (eMHC+μUTRN+; Fig. 3f) could be derived 
from iPS-derived satellite cells (most likely since there are donor-derived satellite cells in 
engrafted muscles; Fig. 3e), but could also form from a non-satellite myogenic precursor 
population that did not seed the satellite cell compartment and did not differentiate into 
myofibers. These results are of particular interest, as activation of corrected satellite cells 
could provide new μUTRN+ myofibers during the progress of the muscular dystrophy, 
slowing the progression of the disease.
Engrafted myofibers exhibit synaptic connections
To address whether engrafted μUTRN+ myofibers exhibited (direct) connection with 
motoneurons, we stained muscle sections with α-Bungarotoxin (α-BTX). Our results clearly 
show the presence of nicotinic Acetylcholine receptors (nAChR) at the neuromuscular 
junction (NMJ) of engrafted fibers (Fig. 4). In WT mice, as expected, utrophin was detected 
solely at the NMJ, along with α-BTX (Fig. 4c), whereas in PBS-injected controls, only α-
BTX was present (Fig. 4b). All together, these data suggest that μUTRN-corrected iPS-
derived myogenic precursors integrate with the neuromuscular system.
Systemic cell transplantation in dKO mice
Since reaching disparate muscle groups is critical when considering clinical application of 
cell therapy for DMD, we assessed engraftment levels following the systemic delivery of 
μUtrn-corrected iPS-derived myogenic precursors. Intra-venous injection of these cell 
preparations resulted in distribution of donor-derived myofibers in several muscles, 
including TA, Gastrocnemius lateralis, and Peroneal (Fig. 5a–c; Supplementary Table S1), 
of all the five mice that had been transplanted. In one of these mice, we were able to 
detected μUTRN-donor-derived myofibers in the diaphragm (Supplementary Fig. S7a). No 
Utrophin signal was detected in any muscles from the PBS-injected mice (Supplementary 
Figs. S7b and S8; Supplementary Table S1). In this cohort of transplanted mice, no 
engraftment was observed in non-skeletal muscle tissues including heart, lung and liver 
(Supplementary Fig. S9). This was also the case following the systemic injection of mouse 
ES cells, as previously reported12.
DISCUSSION
Muscular dystrophies are a genetically and clinically heterogeneous group of neuromuscular 
diseases characterized by progressive skeletal muscle weakening that are commonly 
associated with paralysis and cardiopulmonary complications. Although no effective 
treatment is available at present, one attractive therapeutic approach is to use cell based 
therapies to promote muscle regeneration. Skeletal muscle stem cells represent the ideal cell 
population to be utilized since transplantation of these cells results not only in efficient 
muscle regeneration but also in long-term maintenance through engraftment of the satellite 
stem cell pool; however their therapeutic potential so far has been limited due to their 
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scarcity in adult muscle, and the fact that in vitro expansion of these cells results in reduced 
engraftment ability 32.
Pluripotent stem cells are unique in terms of proliferation and differentiation potential, and 
therefore they represent an advantageous option for therapeutic application. We have 
demonstrated that following introduction of Pax3 or Pax7, transcription factors that play a 
critical role in skeletal myogenesis, both ES and control iPS cells give rise to myogenic 
progenitors endowed with the ability to promote muscle regeneration, to improve the 
contractility of engrafted muscles, and to seed the satellite cell compartment following 
transplantation in dystrophic mice 11–14,33. These encouraging data suggested that a similar 
positive outcome could potentially be achieved with disease-specific iPS cells.
Our findings demonstrate for the first time proof-of-principle for the feasibility of 
combining iPS cell therapy in conjunction with genetic correction to treat muscular 
dystrophy. Although further refinements would be required before converting this proof of 
concept method to a clinical protocol, for example, non-integrating methods of delivering 
Pax3 or Pax7 and iPS reprogramming factors as well as strategies to enhance engraftment 
following systemic delivery, these data clearly demonstrate i) that non-virally corrected-iPS-
derived myogenic precursors are able to engraft in vivo following local and systemic 
transplantation; ii) that such expression restores components of the DGC and that engrafted 
myofibers exhibit neuromuscular synapses, iii) that muscle strength can be significantly 
improved with this approach, and iv) that grafted μUTRN-corrected myogenic precursors 
seed the satellite cell compartment and contribute to muscle fiber repair, confirming that this 
strategy confers long-term expression of μUTRN protein.
METHODS
Generation of iPS cells and characterization
Tail-tip fibroblast (TTF) cultures were established by trypsin digestion of tail-tip biopsies 
taken from 3 week old dKO mice. Fibroblasts were transduced with Oct3/4, Sox2 and Klf-4, 
and iPS clones were individually isolated as previously described 23. Following initial 
expansion, iPS clones were characterized in vitro for SSEA-1 expression by flow cytometry 
(clone MC-480; eBioscience), as well as immunostaining for Nanog, Oct4, and SSEA-1 
(R&D Systems). Alkaline Phosphatase activity (Millipore) was also evaluated. iPS cells 
were subjected to karyotype analysis by G-banding. For the teratoma assay, one million cells 
suspended in 100μl were injected subcutaneously into Rag2−/−/IL2Rg−/− immunodeficient 
mice (Jackson Laboratory). One month after injection, teratoma was dissected and fixed 
with formalin. Tissues were sectioned and stained with hematoxylin and eosin.
Cell culture
ES and iPS cells were maintained as previously described 12 and differentiated, as follows: 
iPS cells were trypsinized and plated at 50,000 cells/cm2 on a monolayer of MEFs. At day 3, 
a single cell suspension of pluripotent cells was obtained by pre-plating on gelatin in the 
presence of EB medium for 1 hour. These cells were then cultured as cell suspension at 
10,000 cells ml−1 of EB medium, and incubated on a slowly swirling table rotator at 70 rpm 
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(set up inside of the tissue culture incubator). At day 3 of EB differentiation, 0.8 μg ml−1 of 
doxycycline was added to the medium to induce Pax3. At day 5, EBs were trypsinized and 
stained for PDGFαR and Flk-1. Sorted cells were plated onto fresh gelatin coated flasks at 
100,000 cells cm−2 in the presence of proliferation myogenic medium, which consisted of 
IMDM, 15% FBS, 1% Chicken Embryo Extract, 10% horse serum, supplemented with 1 μg 
ml−1 of doxycycline and 5ng ml−1 of bFGF. For terminal differentiation, medium was 
switched to low glucose DMEM, and 5% horse serum (no dox or bFGF).
Plasmids and generation of iPax3-μUTRN iPS cells
We developed a T2 inverted terminal repeat transposon vector (pKt2/μUtrn) carrying a 
7.3kb engineered transgene containing μUtrophin and an iresGFP reporter, which allows for 
the selection of μUTRN-corrected iPS cells. The whole transgene is flanked by the terminal 
inverted repeats (IR/DR), each of which contains two binding sites for the transposase itself 
(DR). Flag-μUtrn was engineered by recombinant PCR using the same primers described 
previously for TAT-μUtr 20, except that BamHI and BstBI were used to cut pFastBac Flag-
Utr 34 to reintroduce the recombined Flag-μUtrn into pFastBac1. Pfu Ultra polymerase was 
used for all PCR, and constructs confirmed by DNA sequence analysis. This Flag-μUtrn 
construct was cloned into the pORF5-mcs vector (Invitrogen), and then a blunted EcoRI-
ClaI iresGFP fragment was cloned into the blunted NdeI site of the pORF5-μUtrn vector. 
Finally the blunted PacI-AsisI transgene containing promoter-μUtrn-iresGFP-pA was cloned 
into pKT2 vector. For transposase, we used pCMV-SB100X (generously provided by Zoltan 
Ivics from Max Delbruck Center for Molecular Medicine, Berlin), which yields high levels 
of transposon integration 28. The inducible iPax3 vector was generated by cloning the full-
length Pax3 coding sequence from Open Biosystems (clone MMM1013-9201572) into 
pSAM2-iresCherry vector. Plasmids were prepared using an Endofree Midiprep kit 
(Nucleobond). For SB transposase-mediated integration of μUtrn-transposon, 3×105 iPS 
cells were nucleofected with 1μg of pCMV-SB100 and 5μg of μUtrn-pKT2 using 
Nucleofector 96-well Shuttle (program CG-108) (Lonza). Corrected iPS cells were purified 
based on sorting for GFP+ cells. The doxycycline tet-responsive Pax3 cells were generated 
by transducing iPS cells with both iPax3/ires-mCherry and rtTA lentiviral constructs. Stable 
iPax3-iPS cells were purified based on mCherry expression by FACS.
RT-PCR and western blot analyses
Real time PCR for pluripotency and muscle specific genes was performed using probe sets 
from Applied Biosystems. In the case of μUtrophin, the gene expression assay was 
customized by Applied Biosystems (Supplementary Table S2). For western blot, cell lysates 
were prepared using 1X RIPA Buffer (ThermoScientific) in combination with Complete 
Protease Inhibitor Cocktail (Roche) and PhosSTOP (Roche). 50μg of protein lysates were 
loaded in each lane, resolved in SDS-PAGE, and transferred to membranes (Immobilon-P; 
Millipore), which were incubated overnight at 4°C with primary antibodies: utrophin mAb 
8A4 (1:50; Santa Cruz), anti-FLAG mAb M2 (1:1000; Sigma), Actin (1:3000; GenScript), 
Pax3 (1:1000; R&D Systems), and GAPDH (1:3000; Abcam). After incubation with HRP-
conjugated secondary antibodies (1:10000, Amersham), membranes were incubated with 
Chemiluminescent Substrate (ThermoScientific) and exposed to film.
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FACS analysis
EB-derived cells were collected with trypsin (2 minutes at 37 °C), washed in staining buffer 
(PBS 2% FBS), suspended in the same buffer containing 0.25 μg/106 cells of Fc block 
(eBioscience) and incubated on ice for 5 minutes. Cells were then incubated on ice for 30 
minutes with specific antibody (1 μg/106cells). For PDGFαR and Flk-1, PE- and APC-
conjugated antibodies were used, respectively (eBioscience). For the characterization of 
myogenic precursors, cells were harvested using dissociation buffer (10 minutes at 37 °C). 
We used the following antibodies: anti-M-cadherin (clone 5; Pharmingen), APC-conjugated 
anti-CXCR4 (BD Biosciences), anti-VCAM1 (eBioscience), and anti-CD56 (Miltenyi) as 
well as PE-conjugated anti-Syndecan4 (Pharmingen). For secondary staining in the case of 
M-cadherin, we used APC-conjugated goat anti-mouse Ig (Pharmingen). Stained cells were 
analyzed and sorted on a FACS Aria (Becton–Dickinson).
Immunofluorescence of cultured cells and tissue sections
Immunofluorescence staining of μUtrophin and representative components of the DGC was 
performed on tissue cryosections. TA muscles were embedded in Tissue-Tek OCT 
compound, and immediately frozen in isopentane cooled in liquid nitrogen. Cut tissues (10–
12μm) were blocked for 30 minutes in 4% BSA and 0.05% Tween-20, followed by 
overnight incubation with specific primary antibody in PBS containing 2% goat serum. 
After three PBS washes, sections were incubated for 45 minutes with secondary antibody. 
All primary antibodies were made in rabbit, as follows: rabbit anti-utrophin polyclonal 
antibody (1:400), rabbit anti-α1-Syntrophyn (1:200) (kindly provided by Stan Froehner, 
University of Washington); rabbit anti-β-Dystroglycan (1:400) (H-242 sc-28535 Santa 
Cruz); rabbit anti-nNOS (1:100) (Sigma); mouse anti-Pax7 (1:250; R&D System MAB 
1675); rabbit anti-Laminin (1:400) (Sigma), chicken anti-GFP (1:250) (ab1390 Abcam), α-
Bungarotoxin (α-BTX) (Invitrogen) and anti-embryonic MyHC (1:20; F1.652, 
Developmental Studies Hybridoma Bank). For Pax7 staining MOM kit (vector laboratory) 
was used following manufacturer’s instruction. For secondary staining, goat Alexa-555 anti-
rabbit or mouse, Alexa-488 anti-rabbit or mouse, Alexa-647 anti-rabbit, and Alexa-488 anti-
chicken (1:1000) were used (Molecular Probes). Control tissues were processed 
simultaneously in the same manner.
For in vitro cultures, cells were maintained on gelatin-coated plates, and processed as 
described above. For nuclear staining, cells were first fixed for 10 minutes at −20°C in 
100% ice-cold methanol, washed twice in PBS, and incubated for 10 minutes with 0.3% 
Triton X-100 in PBS. The following primary antibodies were used: anti-Pax3 (1:100; R&D 
Systems), anti-Myf5 (1:100; C-20 Santa Cruz), anti-MyoD (1:100; Pharmingen), and anti-
MyHC (1:50; M20, Developmental Studies Hybridoma Bank). Alexa fluor 555 and 488 
goat-anti-rabbit (Molecular Probes) were used for secondary staining. DAPI (Sigma) was 
used to counter-stain nuclei.
Mice and Transplantation studies
Animal experiments were carried out according to protocols approved by the University of 
Minnesota Institutional Animal Care and Use Committee. Dystrophin/utrophin deficient 
(mdx;utrn−/−) mice (total of 23 dKO mice) were derived and genotyped as previously 
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described 18. One day before cell transplantation (for both intramuscular or intravenous 
injections), mice were started on an daily immunosuppression regimen (FK-506, also known 
as Tacrolimus) for the duration of the experiment, as previously described 12. Myogenic 
progenitor cells were harvested using dissociation buffer (10 minutes at 37 °C), and then 
injected directly into the left TA muscle (106 cells/10μl PBS) or alternatively, through the 
tail vein for systemic delivery (0.8×106 cells/150μl DMEM 10% FBS). Control mice 
received the same volume of PBS. Mice were injured with 50μl of cardiotoxin (10μM, 
Sigma) only in experiments aimed to investigate the capacity of engrafted satellite cells to 
give rise to myofibers expressing the truncated Utrophin.
Muscle preparation for mechanical studies
For the measurement of contractile properties, mice were anaesthetized with avertin (250 
mg/kg I.P.) and intact tibialis anterior (TA) muscles were dissected and placed in an 
experimental organ bath as previously described in detail 12. Muscles were stimulated by an 
electric field generated between two platinum electrodes placed longitudinally on either side 
of the muscle (Square wave pulses 25 V, 0.2 ms in duration, 150 Hz). Muscles were 
adjusted to the optimum length (Lo) for the development of isometric twitch force and a 5 
min recovery period was allowed between stimulations. Optimal muscle length (Lo) and 
stimulation voltage (25 V) were determined from micromanipulation of muscle length and a 
series of twitch contractions that produced maximum isometric twitch force. For measuring 
fatigue time, muscles were stimulated for 1 minute and the time for force to decline to 30% 
of Fo was measured. In brief, after determination of optimal muscle length (Lo) and 
measurement of maximum isometric tetanic force, total muscle cross–sectional area (CSA) 
was calculated by dividing muscle mass (mg) by the product of muscle length (mm) and 
1.06 mg/mm3, the density of mammalian skeletal muscle. Specific force (sFo) was 
determined by normalizing maximum isometric tetanic force to CSA.
Statistical analysis
Differences between samples were assessed by using 1-way ANOVA. All data are presented 
as mean ± SEM.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Ex vivo correction of dystrophic iPS cells
(a) Scheme of the ex vivo gene therapy approach, which involves (1) reprogramming of 
dystrophic donor-derived fibroblasts into iPS cells, (2) genetic repair of iPS cells with the μ-
Utrn transgene using the Sleeping Beauty transposon system, (3) generation of myogenic 
progenitors from corrected iPS cells through Pax3 induction, and (4) transplantation of 
corrected myogenic precursors into dystrophic donor mice. (b) The Sleeping Beauty 
transposon system: the transposon contains the hEF1α-eIF4g promoter, the μUtrn gene, and 
an iresGFP. The whole transgene is flanked by the terminal inverted repeats (IR/DR, 
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arrowheads) each containing two binding sites for the transposase (DR, yellow arrows). The 
transposase protein SB100X (red spheres) catalyzes integration of the transposon into the 
genome with high efficiency. (c) Left panel: Graphic bars represent percentage of GFP+ 
cells obtained prior to each sorting. Green bars correspond to iPS cells nucleofected with 
pKT2/μUTRN-iresGFP/SB100X, while yellow bars represent controls, iPS cells transduced 
with pKT2/μUTRN-IresGFP only (no transposase). Data are mean ±S.E.M. of 3 independent 
samples. (d) FACS profile for GFP shows stable expression of μUTRN in corrected iPS cells 
(right panel), while control iPS cells are GFP− (left panel). (e) Flow cytometric analyses for 
Flk-1 and PDGFαR expression on day 5 EBs of Pax3-induced uncorrected- (upper panel) 
and corrected-iPS (lower panel) cells. The PDGFαR+Flk-1− cell fraction was gated (red 
square on left panels) and analyzed for the expression of GFP, representing μUTRN+ cells 
(middle panels), and mCherry, representing Pax3+ cells (right panels). (f) Phase contrast 
images of monolayers under proliferation (left) and differentiation (right) culture conditions. 
(g) Immunofluorescence staining for μUTRN (green) in proliferating iPS-derived myogenic 
progenitors (left) and their derivative myotubes (right). Cells are co-stained with DAPI 
(blue). Scale bar is 200μm. (h) qPCR analyses indicate relative expression of μ-utrophin in 
corrected iPS-derived myogenic cells under proliferation (P) and differentiation (D) 
conditions. Actin was used as house-keeping gene. Error bars represent S.E.M. from three 
replicates of three independent experiments. (i) Immunoblotting with anti-UTRN and anti-
FLAG antibodies confirm the presence of 163-kDa μUTRN only in corrected cells.
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Figure 2. Engraftment of μUTRN-corrected iPS-derived myogenic precursors in dKO mice
Serial cross-sections (total length of 1000 μm) of TA muscles harvested from dKO mice that 
had been injected with PBS (contra-lateral leg) (a) or myogenic progenitors (b) were stained 
with antibodies to Utrophin and several members of the dystrophin protein complex, 
including β-DG (β-dystroglycan), α1-SYN (α1-syntrophin), and nNOS (red). These proteins 
were detected only in muscles transplanted with μUTRN-corrected myogenic precursors, in 
which they were found expressed in a contiguous manner across long sections of muscle 
fiber, as shown by the asterisks. Roman numbers within these images indicate the order of 
serial sections. PBS-injected dKO mice showed no signal for any of these proteins. DAPI is 
shown in blue. Scale bar is 50 μm. (c) Quantification of μUTRN + myofibers in these 
engrafted muscles (n=8). For each muscle, 3–4 representative cross-sections at 2 mm 
intervals were counted. For PBS control groups, we examined 20 random sections. Error 
bars represent S.D.
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Figure 3. Functional improvement and satellite cell engraftment of transplanted muscles
(a) Representative examples of isometric force-tracking in TA muscles that had been 
injected with corrected cells or PBS (contra-lateral leg) (green and gray lines, respectively). 
For reference, untreated-dKO and wild-type Bl6 mice controls are shown (dashed and black 
line, respectively). (b–c) Effect of cell transplantation on absolute (F0) and specific (sF0=F0 
normalized to CSA) force, respectively. Error bars represent S.E.M. from a total of 13 
transplanted mice. *P < 0.05, **P < 0.01, and ***P < 0.001. (d) Fatigue index: time for 
force to decline to 30% of maximal value during continuous stimulation of muscle at 150 
Hz. (e) In situ localization images show the presence of donor-derived satellite cells in 
engrafted dKO mice, as evidenced by the presence of Pax7+ (red) GFP+ (green) cells under 
the basal lamina (indicated by arrows). Arrowheads denote endogenous Pax7+ GFP− cells 
satellite cells. (f) Engrafted cells respond to CTX injury, giving rise to new myofibers as 
evidenced by the co-expression of μUTRN (red) and embryonic MHC (green). White arrows 
indicate μUTRN+/eMHC+ donor-derived newly formed myofibers, and arrowheads point to 
μUTRN−/eMHC+ host-derived newly formed myofibers. Scale bar is 50 μm.
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Figure 4. Engrafted μUTRN+ myofibers exhibit direct synaptic connections to motoneurons
Representative images show AChRs labeled with α-bungarotoxin (α-BTX) in TA muscles 
that had been injected with corrected iPS-derived myogenic progenitors (a) or PBS (b). TA 
muscles from WT mice are also shown as a reference (c). Utrophin is indicated in red and α-
BTX is shown in green. DAPI is shown in blue. Scale bar is 50 μm.
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Figure 5. Effective systemic delivery of μUTRN-corrected myogenic progenitors in dKO mice
Representative images reveal engraftment of TA (a), gastrocnemius lateralis (b), and 
peroneal (c) muscles of dKO mice that had received intravenous injection of corrected iPS-
derived myogenic progenitors, as evidenced by staining with anti-utrophin and anti-α1-SYN 
(α1-syntrophin) antibodies. Roman numbers within these images indicate the order of serial 
sections. DAPI is shown in blue. Systemic delivery was performed in 5 dKO mice. Scale bar 
is 50 μm.
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